One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Burford Capital Limited logo
Burford Capital Limited BUR
$ 3.24 -6.36%
report update icon

Quarterly report 2026-Q3
added 11-04-2026

Burford Capital Limited Financial Ratios 2025-2011 | BUR

Brief overview of Burford Capital Limited's financial ratios

The review covers five available annual periods spanning 2020 to 2025.

Key multiples at the end of the period are P/E 44.48x (median 22x), EV/EBITDA 24.69x (median 16.66x), P/S 6.73x (median 6.13x). On average, this basket is 29% above its own five-year medians. The market is pricing in elevated future expectations.

At the current P/E, inverse earnings yield is 2.2%, a useful bridge between price and business earnings.

The latest available business-quality ratios are ROE 2.6%, ROA 0.9%, ROCE 9.5%. Business quality is below comfortable levels on current returns. Better margins or turnover are needed.

What the ratios show

Burford Capital Limited combines weak profitability with valuation above its historical norm, leaving limited cushion.

Annual Financial Ratios Burford Capital Limited

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
44.5 22.0 4.8 64.1 -80.5 12.2 - - - - - - - - -

P/S

6.7 5.9 2.7 6.1 10.6 6.3 - - - - - - - - -

EPS

0.3 0.7 2.8 0.1 -0.1 75.3 82.7 150.7 - - - - - - -

EV (Enterprise Value)

5.73 B 5.67 B 5.37 B 3.75 B 3.77 B 3.22 B 1.35 B 690 M 565 M 372 M 160 M 151 M 24.6 M 12.9 M 12.6 M

EBITDA per Share

1.06 1.78 3.75 0.91 0.33 1.11 - - - - - - - - -

EV/EBITDA

24.7 14.5 6.5 18.8 52.5 - - - - - - - - - -

PEG

0.69 - - - - -0.57 - - - - - - - - -

P/B

0.9 1.0 0.9 0.8 1.1 1.3 - - - - - - - - -

P/CF

-95.9 14.9 -10.8 -4.2 -4.0 11.6 - - - - - - - - -

ROE %

2.56 6.05 26.65 1.75 -1.70 10.10 13.84 - - - - - - - -

ROA %

0.94 2.37 10.46 0.71 -0.77 5.51 6.98 13.69 - - - - - - -

ROCE %

9.48 16.14 35.61 11.19 4.04 14.24 15.25 - - - - - - - -

Current Ratio

1.9 2.1 2.2 2.3 2.3 2.1 2.0 2.4 - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Burford Capital Limited

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.11 0.01 -7.46 -0.17000000000000004 -0.09 0.4 0.14 - 2.79 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

0.45 0.29 -7.18 -0.19 0.11 0.65 0.35 - 3.75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-106.56 -109.47 -106.86 2.20 30.44 3.26 1.17 - 26.65 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-37.96 -39.08 -37.64 1.21 12.41 1.66 0.60 - 10.46 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-93.36 -99.06 -98.96 7.24 43.25 4.41 2.46 - 35.61 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.6 1.5 1.6 1.9 1.9 2.0 2.0 2.1 2.2 2.3 - - - 2.3 - - - 2.6 - - - 2.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Burford Capital Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 50.7 -1.48 % $ 6.09 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 9.03 -4.14 % $ 1.26 B franceFrance
Precision BioSciences Precision BioSciences
DTIL
$ 7.37 6.66 % $ 94.5 M usaUSA
Exelixis Exelixis
EXEL
$ 64.59 -1.88 % $ 17.5 B usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 13.09 -2.68 % $ 374 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 0.85 -4.67 % $ 56.8 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 80.87 -0.63 % $ 19.5 B germanyGermany
Alkermes plc Alkermes plc
ALKS
$ 44.89 -2.79 % $ 7.39 B irlandaIrlanda
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 68.6 -0.77 % $ 1.38 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.11 -7.75 % $ 178 K usaUSA
AC Immune SA AC Immune SA
ACIU
$ 1.98 -7.28 % $ 199 M schweizSchweiz
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 6.51 2.6 % $ 81.7 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 0.63 -5.62 % $ 139 M usaUSA
Altimmune Altimmune
ALT
$ 1.33 -6.03 % $ 117 M usaUSA
AnaptysBio AnaptysBio
ANAB
$ 46.65 -1.58 % $ 1.35 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 252.39 -1.39 % $ 15.3 B danmarkDanmark
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 7.42 -2.37 % $ 203 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 14.7 -1.28 % $ 1.98 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 0.91 -6.96 % $ 242 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 3.97 0.89 % $ 324 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 129.32 -4.69 % $ 6.43 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 75.96 -2.84 % $ 14.5 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 7.23 -1.3 % $ 1.52 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 2.89 -5.25 % $ 200 M britainBritain
Benitec Biopharma Benitec Biopharma
BNTC
$ 7.95 -2.4 % $ 370 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 8.24 2.74 % $ 387 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 141.06 -2.35 % $ 28.1 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 6.9 -5.61 % $ 2.47 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.64 17.17 % $ 56.6 M israelIsrael
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 15.56 13.57 % $ 64.8 M canadaCanada
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 12.36 -9.55 % $ 799 M usaUSA
Immutep Limited Immutep Limited
IMMP
$ 3.11 -9.06 % $ 4.53 B australiaAustralia
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
$ 228.26 -3.46 % $ 13.9 B irlandaIrlanda
BeyondSpring BeyondSpring
BYSI
$ 0.33 -24.42 % $ 13.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 0.94 -7.24 % $ 94.5 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
$ 270.2 1.18 % $ 650 B usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 4.2 -6.67 % $ 398 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.49 1.84 % $ 206 M usaUSA
Codexis Codexis
CDXS
$ 1.0 -5.17 % $ 87.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 7.75 -1.02 % $ 447 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.83 -2.66 % $ 171 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 0.37 -4.06 % $ 43.3 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.06 2.68 % $ 111 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.36 -2.15 % $ 1.82 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 0.9 -9.7 % $ 90.3 M franceFrance
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 0.78 -4.87 % $ 179 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 2.01 -7.59 % $ 11.4 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 345.4 -0.44 % $ 1.21 T usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 24.73 -1.9 % $ 783 M usaUSA